|
|
Active Org.- |
|
Active Indication- |
|
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date20 Jan 1800 |
Assessment of Trough Levels and Efficacy of Infliximab and Adalimumab in Inflammatory Bowel Disease Patients.
This study aims to assess trough, TREM-1 levels and efficacy of IFX and ADA in IBD patients.
Characterization of Adalimumab Concentrations in Pediatric Patients With Inflammatory Rheumatic Disease With and Without Methotrexate (ADA in PiRD)
This study is to assess standardized Adalimumab (ADA) concentrations in Pediatric inflammatory rheumatic diseases (PiRD) patients treated with ADA for ≥ 12 weeks with and without concomitant methotrexate (MTX) therapy and to assess peak and trough ADA concentrations in ADA naïve patients after first ADA administration with and without MTX (pre-phase).
100 Clinical Results associated with CD8 x HIV p7 x CD4
100 Translational Medicine associated with CD8 x HIV p7 x CD4
0 Patents (Medical) associated with CD8 x HIV p7 x CD4